An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acadia Pharmaceuticals announced the grant of inducement awards to new employees under the 2023 Inducement Plan. The awards include non-qualified stock options and restricted stock units. Each stock option has an exercise price of $17.73 per share and will vest over four years, while the RSUs will also vest over four years. The awards were granted as inducements material to the new employees' employment, following Nasdaq Listing Rule 5635(c)(4).
Acadia Pharmaceuticals ha annunciato l'assegnazione di premi incentivanti ai nuovi dipendenti nell'ambito del Piano di Induzione 2023. I premi includono opzioni su azioni non qualificate e unità azionarie vincolate. Ogni opzione su azioni ha un prezzo di esercizio di 17,73 dollari per azione e maturerà nel corso di quattro anni, mentre anche le unità azionarie vincolate matureranno in quattro anni. I premi sono stati concessi come incentivi sostanziali per l'impiego dei nuovi dipendenti, in conformità con la Regola 5635(c)(4) del Regolamento di quotazione del Nasdaq.
Acadia Pharmaceuticals anunció la concesión de premios de incentivo a nuevos empleados bajo el Plan de Inducción 2023. Los premios incluyen opciones de acciones no calificadas y unidades de stock restringidas. Cada opción de compra tiene un precio de ejercicio de 17.73 dólares por acción y se acumulará durante cuatro años, al igual que las unidades de stock restringidas se acumularán en un período de cuatro años. Estos premios se otorgaron como incentivos materiales para el empleo de los nuevos empleados, siguiendo la Regla de Cotización en Nasdaq 5635(c)(4).
아카디아 파마슈티컬스사가 2023년 인센티브 플랜에 따라 신입 직원에게 인센티브 보상을 부여했습니다. 이 보상에는 비자격 주식 옵션과 제한된 주식 단위가 포함됩니다. 각 주식 옵션은 주당 17.73달러의 행사 가격을 가지며 4년에 걸쳐 권리가 부여되며, RSU 또한 4년에 걸쳐 권리가 부여됩니다. 이 보상은 나스닥 상장규칙 5635(c)(4)에 따라 신입 직원들의 고용에 중요한 인센티브로 부여되었습니다.
Acadia Pharmaceuticals a annoncé l'attribution de prix d'incitatifs aux nouveaux employés dans le cadre du Plan d'Incitation 2023. Les prix comprennent des options d'achat d'actions non qualifiées et des unités d'actions restreintes. Chaque option d'achat d'actions a un prix d'exercice de 17,73 dollars par action et se verra attribuer des droits sur quatre ans, tout comme les unités d'actions restreintes qui s'accumuleront également sur quatre ans. Ces prix ont été octroyés comme incitations matérielles à l'emploi des nouveaux employés, conformément à la Règle 5635(c)(4) de cotation au Nasdaq.
Acadia Pharmaceuticals hat die Gewährung von Anreizpreisen an neue Mitarbeiter bekannt gegeben, die unter den Anreizplan 2023 fallen. Die Preise umfassen nichtqualifizierte Aktienoptionen und Restricted Stock Units. Jede Aktienoption hat einen Ausübungspreis von 17,73 US-Dollar pro Aktie und wird über vier Jahre hinweg verfallen, während die RSUs ebenfalls über vier Jahre hinweg verfallen werden. Die Prämien wurden als materielle Anreize für die Beschäftigung neuer Mitarbeiter gemäß der Nasdaq Listing Rule 5635(c)(4) gewährt.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units (“RSUs”) to six new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to $17.73 per share, Acadia’s closing trading price on April 10, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees’ continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What type of awards were granted to new employees at Acadia Pharmaceuticals?
New employees at Acadia Pharmaceuticals were granted non-qualified stock options and restricted stock units.
How many shares of common stock can be purchased through the stock options?
21,659 shares of common stock can be purchased through the stock options.
What is the exercise price per share for the stock options?
The exercise price per share for the stock options is $17.73, based on Acadia's closing trading price on April 10, 2024.
How long will it take for the stock options to vest completely?
The stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the rest vesting monthly over 36 months.
What is the vesting schedule for the restricted stock units (RSUs)?
The RSUs will vest over four years, with 50% of the shares vesting on the second anniversary of the grant date, and the remaining shares vesting in two equal annual installments measured from the second anniversary.
What is the purpose of granting these awards to new employees?
The awards were granted as inducements material to the new employees' employment, following Nasdaq Listing Rule 5635(c)(4).
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
